PT  - JOURNAL ARTICLE
AU  - Arce, Julio S. Solís
AU  - Warren, Shana S.
AU  - Meriggi, Niccoló F.
AU  - Scacco, Alexandra
AU  - McMurry, Nina
AU  - Voors, Maarten
AU  - Syunyaev, Georgiy
AU  - Malik, Amyn Abdul
AU  - Aboutajdine, Samya
AU  - Armand, Alex
AU  - Asad, Saher
AU  - Augsburg, Britta
AU  - Bancalari, Antonella
AU  - Nyqvist, Martina Björkman
AU  - Borisova, Ekaterina
AU  - Bosancianu, Constantin Manuel
AU  - Cheema, Ali
AU  - Collins, Elliott
AU  - Farooqi, Ahsan Zia
AU  - Fracchia, Mattia
AU  - Guariso, Andrea
AU  - Hasanain, Ali
AU  - Kamwesigye, Anthony
AU  - Kreps, Sarah
AU  - Levine, Madison
AU  - Littman, Rebecca
AU  - Platas, Melina
AU  - Ramakrishna, Vasudha
AU  - Shapiro, Jacob N.
AU  - Svensson, Jakob
AU  - Vernot, Corey
AU  - Vicente, Pedro C.
AU  - Weissinger, Laurin B
AU  - Zhang, Baobao
AU  - Karlan, Dean
AU  - Callen, Michael
AU  - Teachout, Matthieu
AU  - Humphreys, Macartan
AU  - Omer, Saad B.
AU  - Mobarak, Ahmed Mushfiq
TI  - COVID-19 Vaccine Acceptance and Hesitancy in Low and Middle Income Countries, and Implications for Messaging
AID  - 10.1101/2021.03.11.21253419
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.11.21253419
4099  - http://medrxiv.org/content/early/2021/03/13/2021.03.11.21253419.short
4100  - http://medrxiv.org/content/early/2021/03/13/2021.03.11.21253419.full
AB  - Background As vaccination campaigns are deployed worldwide, addressing vaccine hesitancy is of critical importance to ensure sufficient immunization coverage. We analyzed COVID-19 vaccine acceptance across 15 samples covering ten low- and middle-income countries (LMICs) in Asia, Africa, and South America, and two higher income countries (Russia and the United States).Methods Standardized survey responses were collected from ‘45,928 individuals between June 2020 and January 2021. We estimate vaccine acceptance with robust standard errors clustered at the study level. We analyze stated reasons for vaccine acceptance and hesitancy, and the most trusted sources for advice on vaccination, and we disaggregate acceptance rates by gender, age, and education level.Findings We document willingness to take a COVID-19 vaccine across LMIC samples, ranging from 67% (Burkina Faso) to 97% (Nepal). Willingness was considerably higher in LMICs (80%) than in the United States (65%) and Russia (30%). Vaccine acceptance was primarily explained by an interest in personal protection against the disease (91%). Concern about side effects (40%) was the most common reason for reluctance. Health workers were considered the most trusted sources of information about COVID-19 vaccines.Interpretation Given high levels of stated willingness to accept a COVID-19 vaccine across LMIC samples, our study suggests that prioritizing efficient and equitable vaccine distribution to LMICs will yield high returns in promoting immunization on a global scale. Messaging and other community-level interventions in these contexts should be designed to help translate intentions into uptake, and emphasize safety and efficacy. Trusted health workers are ideally positioned to deliver these messages.Funding Beyond Conflict, Bill and Melinda Gates Foundation, Columbia University, Givewell.org, Ghent University, HSE University Basic Research Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence Initiative, London School of Economics and Political Science, Mulago Foundation, NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Oxford Policy Management, Social Science Research Council, Trinity College Dublin COVID19Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale Institute for Global Health, Yale Macmillan Center, and anonymous donors to IPA and Y-RISECompeting Interest StatementThe authors have declared no competing interest.Funding StatementBeyond Conflict, Bill and Melinda Gates Foundation, Columbia University, Givewell.org, Ghent University, HSE University Basic Research Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence Initiative, London School of Economics and Political Science, Mulago Foundation, NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Oxford Policy Management, Social Science Research Council, Trinity College Dublin COVID19 Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale Institute for Global Health, Yale Macmillan Center, and anonymous donors to IPA and Y-RISE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by multiple IRBs and they are listed in the appendix.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and output of the analysis can be consulted here https://wzb-ipi.github.io/covid_vaccines/replication.html. https://wzb-ipi.github.io/covid_vaccines/replication.html